R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial

Chamuleau, MED; Stenner, F; Chitu, DA; Novak, U; Minnema, MC; Geerts, P; Stevens, WBC; Zenz, T; Imhoff, GWV; Wu, KL; Demandt, AMP; Kersten, MJ; Terpstra, WE; Tick, LW; Deeren, D; Neste, EV; Gregor, M; Veelken, H; Böhmer, LH; Caspar, CB; Mutsaers, P; Refos, JM; Sewsaran, R; Fu, LP; Seefat, RL; Groot, CAUD; Dirnhofer, S; Brand, MV; de Jong, D; Nijland, M; Lugtenburg, P

Chamuleau, MED (通讯作者)，Univ Amsterdam, Dept Haematol, Locat VU, Med Ctr, NL-1081 HV Amsterdam, Netherlands.

LANCET HAEMATOLOGY, 2023; 10 (12): E966

Abstract

Background Patients with newly diagnosed high-risk Burkitt lymphoma are treated with high-intensity immune-chemotherapy regimens such as R-CODOX-M/R-I......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索